The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man

K K Adjepon-Yamoah, G Edwards, A M Breckenridge, M L Orme, S A Ward, K K Adjepon-Yamoah, G Edwards, A M Breckenridge, M L Orme, S A Ward

Abstract

1 The pharmacokinetics of diethylcarbamazine (DEC) were studied in twelve patients with chronic renal function impairment. 2 Selected pharmacokinetic parameters, plasma half-life (T1/2), area under the plasma concentration-time curve (AUC), elimination rate constant (Kel) and 24 h urinary excretion were regressed versus parameters indicative of renal function. 3 Significant negative correlations were observed between creatinine clearance and both plasma T1/2 and log10 T1/2. 4 Significant positive correlations were obtained between (a) creatinine clearance and elimination rate constant of DEC and (b) reciprocal serum creatinine and l/T1/2. Creatinine clearance was significantly and positively correlated with 24 h urinary excretion of DEC. 5 No significant correlations were observed between age, sex or weight and renal function but DEC excretion did appear to decrease with increasing urinary pH. 6 Plasma half-life, and area under the plasma concentration-time curve were increased and 24 h urinary excretion of DEC was significantly reduced in patients with chronic renal function impairment, compared with normal volunteer subjects receiving an identical dosage of DEC at acidic urinary pH.

References

    1. J Pharm Pharmacol. 1965 Oct;17(10):628-39
    1. Xenobiotica. 1972 Jan;2(1):59-68
    1. Clin Pharmacokinet. 1976;1(2):121-5
    1. Clin Pharmacokinet. 1976;1(2):99-120
    1. J Chromatogr. 1979 Dec 1;164(4):521-6
    1. Clin Pharmacol Ther. 1981 Oct;30(4):551-7
    1. Xenobiotica. 1981 Apr;11(4):281-4
    1. Br J Clin Pharmacol. 1981 Dec;12(6):807-12
    1. Trans R Soc Trop Med Hyg. 1950 Sep;44(2):153-92
    1. Br J Pharmacol Chemother. 1955 Dec;10(4):397-405

Source: PubMed

3
Prenumerera